<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon syndrome</z:e> (SNS) is characterized by the association of ischaemic cerebrovascular events and widespread <z:e sem="disease" ids="C0085642" disease_type="Disease or Syndrome" abbrv="">livedo racemosa</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Its pathophysiology is still controversial </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to evaluate the prevalence of <z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">factor V Leiden mutation</z:e> in consecutive patients referred for SNS according to <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) status </plain></SENT>
<SENT sid="3" pm="."><plain>Fifty-three Caucasian patients were enrolled from 1996 to 2001 </plain></SENT>
<SENT sid="4" pm="."><plain>Diagnosis of SNS was based on the presence of a widespread <z:e sem="disease" ids="C0085642" disease_type="Disease or Syndrome" abbrv="">livedo racemosa</z:e> and at least one clinical neurologic ischaemic event </plain></SENT>
<SENT sid="5" pm="."><plain>The following investigations were performed: detection of antithrombin III, protein C and <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiency</z:e>, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, anticardiolipin and anti-beta2 <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I antibodies, biologic false-positive test for <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e>, and <z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">factor V Leiden mutation</z:e> by direct genomic analysis </plain></SENT>
<SENT sid="6" pm="."><plain>Fisher's test and t-test were used for statistics </plain></SENT>
<SENT sid="7" pm="."><plain>Detection of aPL on multiple determinations was negative in 31 patients (group 1) and positive in 22 patients (group 2) </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">Factor V Leiden mutation</z:e> was detected in six patients (11.3%), heterozygous in <z:hpo ids='HP_0000001'>all</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The frequency of this mutation was statistically higher in group 1 (6/31, 19.3%) than in group 2 (0/22; P = 0.035) </plain></SENT>
<SENT sid="10" pm="."><plain>Within aPL-negative SNS, the comparison of patients with versus without <z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">factor V Leiden mutation</z:e> showed no difference for clinical data or familial history of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>A high prevalence of heterozygous factor V mutation was found in aPL-negative patients with SNS </plain></SENT>
<SENT sid="12" pm="."><plain>This finding adds further arguments to consider SNS as a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> entity </plain></SENT>
</text></document>